Latest Breaking News On - லிண்டி ட்யுரெஂட் - Page 2 : comparemela.com
Accsys Tech News Headlines AXS Share News Financial News Articles for Accsys Technologies Plc Ord Eur0 05 updated throughout the day
lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.
Investegate |Scancell Hlds Announcements | Scancell Hlds: Lindy Durrant appointed CEO of Scancell
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
COVID-19: New vaccine in development has insurance against coronavirus mutations
originalfm.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from originalfm.com Daily Mail and Mail on Sunday newspapers.
| UPDATED: 08:09, Sun, Feb 14, 2021
Link copied
Boots answers common questions about the coronavirus vaccine Sign up to receive our rundown of the day s top stories direct to your inbox
SUBSCRIBE Invalid email
When you subscribe we will use the information you provide to send you these newsletters. Sometimes they ll include recommendations for other related newsletters or services we offer. Our Privacy Notice explains more about how we use your data, and your rights. You can unsubscribe at any time.
Scientists from the University of Nottingham are developing a “universal” coronavirus jab that would target the core of COVID-19 instead of only the spike protein. If the vaccine is successful, it would minimise the need to adjust existing jabs when the virus mutates.
Scancell Shares Rise As It Chooses Vaccine Candidate For Development
Fri, 18th Dec 2020 10:26
(Alliance News) - Shares rose in Scancell Holdings PLC on Friday as it has selected its Covid-19 vaccine candidate SN14 for further development and clinical trials.
Shares in the novel immunotherapies developer were 14% higher at 13.68 pence on Friday in London.
The SN14 vaccine candidate targets both the SARS-CoV-2 nucleocapsid protein and the key receptor-binding domain of the spike protein. It is based on a modification of Scancell s ImmunoBody DNA vaccine technology.
Scancell had initially evaluated 15 vaccine candidates containing different S and N components for the best T cell and antibody responses. SN14 elicited high-titre anti-S virus neutralising antibodies together with high avidity T cells against both the S and N proteins.